tbuckley/cabot-search huggingface dataset:
Four years survival in autologous stem cell transplantation with moderate dose of idarubicin and busulphan as conditioning regimen in acute myelogenous leukemia
Authors: M. A. Mashhadi Sr., M. Ramzi, K. Alimoghaddam
Journal: Journal of Clinical Oncology (2008)

18029 Background: Over exceed 50% of patients with AML still relapsed after autologous stem cell transplantation. We investigated the efficacy and feasibility of a new conditioning regimen consisting of moderate dose ofIdarubicine plus conventional dose of oral Busulfan in patients undergoin autologous transplantation that they had not favorable cytogenitic and had not received high dose therapy with Cytarabine or other drugs. Methods: Patients (n = 10) were given three days bolous infusion of IDA followed by four days of oral Busulfan as conditioning regimen. Unpurged Peripheral blood stem cells were used in all cases. All cases were in first complete remission (CR1). The cause of this selection of patients in first remission was: the patients had not received high dose chemotherapy and in available cytogenitic study the patients with favorable cytogenetic such as A.M.L (M3); T (8:21); inv: 16 were excluded from this study. The median CD34+ cell infused was 8 ∉106/kg. Results: The transplant related mortality was occurred in one case (refactory thrombocytopenia and due to this problem CNS hemorrhage was occurred). The median days to neutrophil > (0.5 ∉ 109) and platlet > (20 ∉10 9/kg) were +9 (4–12); +16 (2–30) respectively. Patients needed transfusion of a median of 15 platlet units and 7 blood units; respectivity; 6 out of 10 patients (60%) had variable grade of mucositis (three cases had grade III; Two grade II and one case had grade I). After median follow up of 48 months from ASCT; 8 patients out of 10 (80%) are alive in continuous complete remission. One case had relapse after 6 months of transplantation. Conclusions: Our data and experience demonstrated the efficacy and feasibility of a conditioning regimen based on moderate dose of IDA plus Busulphan in AML. Results concerning anti leukemic efficacy are promising; but need to be confirmed on larger series. No significant financial relationships to disclose.
Clinical Aspects of the Electrocardiogram. A Manual for Physicians and Students.
Authors: Harold Ensign Bennett Pardee
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
La lutte internationale contre le cancer
Authors: Jacques Bandaline, Justin Godart
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vaccination préventive et curative du cobaye et du lapin contre la tuberculose humaine, ses indications et ses effets chez l'homme.
Authors: Jules Auclair
Journal: JAMA (1930)

In this treatise, Auclair's experiments of recent years on immunization against tuberculosis are compiled in book form. The relation of the pancreas to immunity is stressed, and good results are reported from vaccination against tuberculosis with tubercle bacilli treated with pancreatic juice. His success with other forms of vaccination, as with dead bacilli and small doses of live bacilli, confirms what has already been reported many times.
Abstract 602: FoxO3 Mediates Urotensin-II-induced MMP2 Expression In Pulmonary Artery Smooth Muscle Cells
Authors: Isabel Diebold, Andreas Petry, Max Burger, Talija Djordjevic, John Hess, Agnes Görlach
Journal: Circulation (2007)

Vascular remodeling in pulmonary hypertension (PH) results from persistent vasoconstriction, extracellular matrix degradation, cell migration and proliferation of vascular cells. However, the mechanisms linking these events are not well understood. Human urotensin-II (hU-II) is a newly identified vasoactive peptide which by binding to a G-protein-coupled receptor termed GPR-14, acts as the most potent vasoconstrictor known. Although hU-II has been associated with vascular remodeling in PH, its precise role in regulating remodeling processes is not well understood. Since degradation of the extracellular matrix plays a pivotal role in pulmonary vascular remodeling, we investigated whether hU-II is linked to expression and activity of matrix metalloproteinases (MMP) in pulmonary artery smooth muscle cells (PASMC). By immunohistochemistry we found high levels of GPR-14 and MMP2 in the media and intima of pulmonary vessels in tissue samples from patients with pulmonary vascular remodeling. In vitro experiments confirmed that hU-II time-dependently enhanced MMP2 mRNA and protein levels as well as MMP2 activity determined by zymography in PASMC. Actinomycin D inhibited hU-II-stimulated MMP2 expression indicating the involvement of a transcriptional mechanism. Bioinformatic analysis of the MMP2 promoter revealed the presence of a consensus site for FoxO3. Reporter gene assays confirmed that hU-II can increase the activity of FoxO transcription factors. Downregulation of FoxO3 by siRNA inhibited hU-II-induced MMP2 expression. Conversely, overexpression of wild type or constitutively active FoxO3 increased MMP2 expression. Consistently, hU-II increased FoxO3 levels in PASMC. FoxO3 was also strongly expressed in the media and intima of pulmonary vessels in tissue samples from patients with pulmonary vascular remodeling. In summary, this study demonstrates that hU-II induces MMP2 via FoxO3. Since the hU-II receptor GPR-14, MMP2 and FoxO3 colocalized in the media and intima of pulmonary vessels from patients with pulmonary vascular remodeling, these findings suggest an important role of this pathway in promoting pulmonary vascular remodeling and implicate FoxO3 as a potential therapeutic target for combating vascular remodeling in PH.
The Literature of American School and College Athletics.
Authors: W. Carson. Ryan, Henry S. Pritchett
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Die Physiologie und Pathologie der Blutgerinnung.
Authors: Bernhard Stuber, Konrad Lang
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3705: Risk factors and Clinical Outcomes for Contrast Induced Nephropathy Post Percutaneous Coronary Intervention in Patients with Normal baseline Renal Function
Authors: Eric Chong, Liang Shen, Yiong H Chan, Huay C Tan
Journal: Circulation (2007)

Background: Contrast induced nephropathy (CIN) is an important complication post percutaneous coronary intervention (PCI). We examine the risk factors for developing CIN in patients with normal baseline renal function so that prophylactic measures may be undertaken to prevent its development. Methods: A cohort of 5086 patients with normal baseline renal function (defined as serum creatinine &lt;1.5mg/dl) who did not receive prophylactic treatment while undergoing PCI (primary or elective) between May 1996 to March 2007 in our centre was enrolled in the study. We examine the occurrence of CIN (defined as &gt;25% increase from baseline creatinine within 48 hours post PCI) in 3036 subjects of this cohort with available creatinine data and aim to identify the clinical predictors. Results: CIN occurred in 7.3% of the patients. The mean age of these patients was 57.5 yrs, 78.7% were men, and 34.6% had diabetes mellitus. Clinical predictors for CIN were age (OR 6.4, 95% CI 0.1–13.3, p=0.042), female gender (OR 2.0, 95% CI 1.5–2.7, p=0.001), lower left ventricular ejection fraction (OR 1.02, 95% CI 1.01–1.04, p=0.01), anemia with hemoglobin &lt;11mg/dl (OR 1.5 (95% CI 1.01–2.4, p=0.044) and systolic hypotension with blood pressure &lt;100mmHg on admission(OR 1.5, 95% CI 1.01–2.2, p=0.004). While there was no increase in the incidence of CIN among diabetics and nondiabetics (8.2% vs 6.8%, p=0.18), those who are on insulin therapy are at the highest risk compared with diabetics on diet control and oral hypoglycemic drugs (18.9% vs 3.6% vs 6.8%, p=0.001). There was no significant difference between patients who underwent primary vs elective PCI (7.0% vs. 6.6% p=0.75). Patients who developed CIN had higher mortality rate at 1 month (14.5% vs 1.1%, p&lt;0.001) and 6 month (17.8% vs 2.2%, p&lt;0.001) Conclusion: Patients with normal baseline renal function undergoing PCI are also at risk of developing CIN with resultant higher mortality. Age, female, insulin dependent diabetes mellitus, hypotension, anemia, low left ventricular ejection fraction are predictors of CIN. Such patients should also be considered CIN prophylactic therapy.
Abstract 15574: Adipose Tissue-Derived Mesenchymal Stem Cells with Myocardin-A and Telomerase Co-Expression Possess Augmented Capacity of Proliferation and Promyogenic Activities
Authors: Rosalinda Madonna, Raffaele De Caterina, James T Willerson, Yong-Jian Geng
Journal: Circulation (2011)

Background and Objective: Myocardin-A (McA) acts as a nuclear transcription cofactor for myogenic gene expression while telomerase reverse transcriptase (TERT) maintains the telomere length and pre...
Practical Electrotherapeutics and X-Ray Therapy.
Authors: James Madison Martin
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Design and synthesis of vWF TASP, a novel synthetic peptide mimicking the A1 domain of the von Willebrand factor
Authors: T. Kovacsovics, S. Mathieu, A. Fernandez-Carneado, D. Grell, M. Schapira, O. Spertini, G. Tuchscherer, J. Hauert
Journal: Blood (2001)
Tumor progression and chemosensitivity to uracil/tegafur in relation to the apoptosis related protens in gastric cancer
Authors: S. Tsujitani, S. Tatebe, A. Kondo, N. Kaibara
Journal: Journal of Clinical Oncology (2004)

4072 Background: Apoptosis related proteins including p53 and p21 regulate cell cycle under exposure of anticancer drugs. The Bax and Mcl-1 gene are members of the Bcl-2 family. Bcl-2 and Mcl-1 are blockers of cell death, whereas Bax and Bcl-Xs are promoters of apoptosis. Methods: To study apoptosis related protein expression and their impact on patient's survival time and chemosensitivity to postoperative UFT [uracil/tegafur 4:1], we examined mutant p53, p21, bax and Mcl-1 protein expression using immunohistochemical staining in 125 surgically resected gastric carcinomas invading the serosa (T3). Results: Expression of mutant p53, p21, Bax and Mcl-1 proteins were detected in 64%, 48%, 39% and 75% of patients, respectively. Mutant p53(+), p21(-) or Mcl-1(+) tumor was frequently observed in more advanced carcinomas. Patients with mutant p53(-), p21(+) or Mcl-1(-) tumor had better survival rates than those with mutant p53(+), p21(-) or Mcl-1(+) tumor, respectively. More p21(+) or Bax(+) cases and less mutant p53(+) or Mcl-1(+) cases were found in differentiated carcinoma. In patients with mutant p53(+), p21(+), Bax(-), or Mcl-1(-) tumor, no survival benefit was obtained by using UFT. In patients with mutant p53 tumor, however, 5-year survival rate of those given UFT was 72%, significantly superior to 35% of those not given the drug (P<0.05). In patients with p21(-) tumor, 54% of patients given UFT survived for 5 year, whereas all patients not given UFT died within 4 years (P<0.05). In patients with Bax(+) tumor, 5-year survival rates were 61% in those given UFT and 31% in those not given UFT (P<0.05). In patients with Mcl-1(+) tumor, 5-year survival rate of those given UFT was 57%, being significantly better than 32% of those not given the drug (P<0.01). Conclusions: These results indicate that the relationship of expression levels of p53, p21, Bax and Mcl-1 is important for predicting the efficacy of postoperative UFT. Therefore, patients with T3 gastric carcinoma should be selected for UFT treatment based on the expression of apoptosis related proteins in tumor cells. No significant financial relationships to disclose.
Reply
Authors: Tamer Abdelrahman, Joseph Hughes, Janice Main, John McLauchlan, Mark Thursz, Emma Thomson
Journal: Hepatology (2014)

Potential conflict of interest: Nothing to report. We agree with Martin et al. that, as yet, late recurrence of hepatitis C virus (HCV) following treatment has not been studied in this highly exposed group of patients. To clarify the point made in our study,1 the majority of cases labeled as HCV reinfection within the 24‐week window posttreatment are likely to represent viral rebound rather than reinfection, even in the presence of a switch in genotype or subtype. In the absence of detailed sequencing data, it indeed seems likely that patients with recurrent HCV infection have a high rate of reinfection,2 although there is a need to carry out an appropriately designed study to confirm this, as some studies in other highly exposed cohorts have shown that relapse is associated with recrudescence of similar strains, others have lacked analysis of paired samples, and none have employed a next‐generation sequencing approach.3 In the meantime, the proposed adjustment to the reinfection rate following removal of the 7% of patients who relapsed within the 24‐week posttreatment would seem entirely appropriate.5 We also agree that retreatment is indicated in patients with recurrent HCV infection. The role of the emergence of resistant variants will be of particular interest as direct‐acting antivirals (DAAs) are rolled out, in particular when interferon‐free regimens are used, as interferon resistance is likely to be heavily influenced by the host response and is unlikely to occur solely due to mutations within the viral genome.
Fighters of Fate. A Story of Men and Women Who Have Achieved Greatly Despite the Handicaps of the Great White Plague.
Authors: Jay Arthur Myers
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Progress In Clinical Pathology.
Authors: Mario Stefanini
Journal: Annals of Internal Medicine (1974)

well, and incorrectly defining the mor¬ phologic index as the number of uniformly staining bacilli  unit of leprous tissue instead of per 100 ba¬ cilli. Domonkos himself, incidentally, does not call the disease Hanseniasis. He calls it, properly, leprosy. Regrettably, the  is rather non¬ committal about the dosage of many drugs, particularly corticosteroids; even in diseases like bullous pemphigoid or painful herpes zoster, or Ste¬ vens-Johnson syndrome, where un¬ usually large doses may be necessary initially, this is not often stated. In¬ deed, it is suggested that cortico¬ steroids in zoster may be dangerous; this is an obsolete view. Optic atrophy is not mentioned as a likely ultimate side effect of treatment with Diodoquin (diiodohydroxyquin), a risky oversight. The chief dangers of sulfone ther¬ apy are not, as he says, anemia and dermatitis. Dermatitis is a very rare side effect. The chief dangers are methemoglobinemia and hemolysis (which does, of course, lead to ane¬ mia). Leukopenia is next in line. But such criticisms are trivial. The preeminent position of Andrews' little text has been firmly main¬ tained by Domonkos in this new edi¬ tion. It is still, as it has been for more than 40 years, the finest small text¬ book of dermatology in the world, and
Costs, Risks, and Benefits of Surgery.
Authors: John P. Bunker, Benjamin A. Barnes, Frederick Mosteller
Journal: Annals of Internal Medicine (1978)

This book is written for physicians and surgeons, public health planners, policy analysts, faculty and students of medical schools, members of legislatures and their staffs, and others who ask 'How can we get the most from the resources we allocate to medical care?'This question, basic to economics, is relatively new to the health field.It is the raison d'&tre for health planning.Costs, Risks, and
Abstract 20229: Pulmonary Vascular Response Patterns to Exercise Predict Exercise Capacity and Outcomes in Heart Failure
Authors: Ryan M Murphy, Ravi Shah, Rajeev Malhotra, Paul P Pappagianopoulos, Stacyann S Hough, Kenneth D Bloch, David M Systrom, Marc J Semigran, Gregory D Lewis
Journal: Circulation (2010)
The Activation Of M2 Polarized Tumor-Associated Macrophages In The Microenvironment Of NK/T-Cell Lymphoma and The Characteristics Of Cytokine Spectrum
Authors: Bing Bai, Hui-qiang Huang, Qi-chun Cai, Xiao-Xiao Wang, Qingqing Cai, Yan Gao, Wei Zhao
Journal: Blood (2013)
Growth of lanthanide-doped LiGdF4 nanoparticles induced by LiLuF4 core as tri-modal imaging bioprobes
Authors: Xuesong Zhai, Pengpeng Lei, Peng Zhang, Zhuo Wang, Shuyan Song, Xia Xu, Xiuling Liu, Jing Feng, Hongjie Zhang
Journal: Biomaterials (2015)
Europe set to tighten rules on breast implants.
Authors: Rory Watson
Journal: BMJ (2001)

The European Commission is proposing tighter controls on the safety of breast implants.

Its move comes in response to a lengthy campaign by women's groups and as part of an initiative to improve quality of service, information provision, and post-surgical follow up. The commission is recommending that governments of European Union states introduce legislation that would require anyone performing implant surgery to provide comprehensive information to the patient beforehand.

The plans foresee the introduction of national registers that would contain details of every implant operation carried out in the European Union.